Palbociclib Intermediate CAS 1016636-76-2 Ubunyulu > 99.0% (HPLC) Factory
I-Ruifu Chemical Supply Palbociclib Related Intermediates:
Palbociclib CAS 571190-30-2
5-Bromo-2,4-Dichloropyrimidine CAS 36082-50-5
I-5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine CAS 733039-20-8
tert-Butyl 4-(6-Nitropyridin-3-yl)piperazine-1-Carboxylate CAS 571189-16-7
tert-Butyl 4-(6-Amino-3-Pyridyl)piperazine-1-Carboxylate CAS 571188-59-5
6-Bromo-2-Chloro-8-Cyclopentyl-5-Methylpyrido-[2,3-d]pyrimidin-7 (8H)-enye CAS 1016636-76-2
I-2-Chloro-8-Cyclopentyl-5-Methyl-8H-Pyrido[2,3-d]pyrimidin-7-enye CAS 1013916-37-4
Igama leMchiza | 6-Bromo-2-Chloro-8-Cyclopentyl-5-Methylpyrido-[2,3-d]pyrimidin-7(8H)-enye |
Izithethantonye | Palbociclib-Pb3 |
Inombolo yeCAS | 1016636-76-2 |
Inombolo yeCAT | RF-PI1849 |
Ubume beStokhwe | Kwi-Stock, iMveliso yoMveliso ukuya kwiiToni |
Ifomula yeemolekyuli | I-C13H13BrClN3O |
Ubunzima beMolekyuli | 342.63 |
Uphawu | Ruifu Chemical |
Into | Iinkcukacha |
Imbonakalo | Umgubo oMhlophe ukuya koMthubi oKhanyayo |
Ubunyulu / Indlela yokuHlalutya | >99.0% (HPLC) |
Izinto ezinxulumeneyo | <1.00% |
Ilahleko ekomisweni | <0.50% |
Amanzi (KF) | <0.50% |
Umgangatho woVavanyo | Umgangatho woShishino |
Ukusetyenziswa | Umbindi wePalbociclib (CAS: 571190-30-2) |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, 25kg/Igubu lekhadibhodi, okanye ngokwemfuno yomthengi
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ukukhanya kunye nokufuma
I-6-Bromo-2-chloro-8-cyclopentyl-5-methylpyrido-[2,3-d]pyrimidin-7 (8H)-enye (CAS: 1016636-76-2) iphakathi kwePalbociclib (CAS: 571190- 30-2).I-Palbociclib lichiza lokunyanga i-ER-positive kunye ne-HER2-negative umhlaza webele ophuhlisiwe.I-Palbociclib yi-inhibitor ekhethiweyo ye-cyclin-dependent kinases CDK4 kunye ne-CDK6.Ngomhla we-3 kaFebruwari, i-2015, i-US FDA yavuma i-Pfizer's Palbociclib (igama lokuthengisa: Ibrance) kunyango lomhlaza webele ophezulu / we-metastatic kubasetyhini be-postmenopausal.IPalbociclib yi-CDK4/6 inhibitor yokuqala ukufumana imvume ye-FDA.